Cargando…

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD

PURPOSE: Due to the burden of COPD in Japan, new pharmacologic treatments are needed to meet patient requirements. This study assessed the efficacy and safety of glycopyrronium (GP) delivered via metered dose inhaler (MDI) in Japanese patients with moderate-to-severe COPD. METHODS: This Phase IIb, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Yasushi, Nakatani, Yuji, Ide, Yumiko, Sekino, Hisakuni, St Rose, Earl, Siddiqui, Shahid, Maes, Andrea, Reisner, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905841/
https://www.ncbi.nlm.nih.gov/pubmed/29695902
http://dx.doi.org/10.2147/COPD.S159246
_version_ 1783315318309912576
author Fukushima, Yasushi
Nakatani, Yuji
Ide, Yumiko
Sekino, Hisakuni
St Rose, Earl
Siddiqui, Shahid
Maes, Andrea
Reisner, Colin
author_facet Fukushima, Yasushi
Nakatani, Yuji
Ide, Yumiko
Sekino, Hisakuni
St Rose, Earl
Siddiqui, Shahid
Maes, Andrea
Reisner, Colin
author_sort Fukushima, Yasushi
collection PubMed
description PURPOSE: Due to the burden of COPD in Japan, new pharmacologic treatments are needed to meet patient requirements. This study assessed the efficacy and safety of glycopyrronium (GP) delivered via metered dose inhaler (MDI) in Japanese patients with moderate-to-severe COPD. METHODS: This Phase IIb, multicenter, randomized, double-blind, 7-day, crossover study compared GP MDI 28.8, 14.4, and 7.2 μg with placebo MDI (all administered as two inhalations, twice daily). The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV(1)) on Day 8. Secondary endpoints included FEV(1) area under the curve from 0 to 2 hours (AUC(0–2)) and peak change from baseline in FEV(1) on Days 1 and 8 and forced vital capacity AUC(0–2) on Day 8. Safety was also assessed. ClinicalTrials.gov Identifier: NCT03256552; http://www.ClinicalTrials.gov. RESULTS: Sixty-six patients were randomized and 62 were included in the modified intent-to-treat population (mean age 67.5 years). All three GP MDI doses significantly improved change from baseline in morning pre-dose trough FEV(1) on Day 8 compared with placebo MDI (least squares mean differences 108–131 mL; all p<0.0001). Significant improvements in secondary efficacy endpoints were also observed for all three GP MDI doses compared with placebo MDI (all p<0.0001). Dose–response plateaued at GP MDI 14.4 μg. No significant safety findings were observed with any GP MDI dose or placebo MDI. CONCLUSIONS: The results of this study suggest that GP MDI 14.4 μg (7.2 μg per inhalation) is the most appropriate dose for use in Phase III studies in Japanese patients with moderate-to-severe COPD.
format Online
Article
Text
id pubmed-5905841
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59058412018-04-25 Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD Fukushima, Yasushi Nakatani, Yuji Ide, Yumiko Sekino, Hisakuni St Rose, Earl Siddiqui, Shahid Maes, Andrea Reisner, Colin Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: Due to the burden of COPD in Japan, new pharmacologic treatments are needed to meet patient requirements. This study assessed the efficacy and safety of glycopyrronium (GP) delivered via metered dose inhaler (MDI) in Japanese patients with moderate-to-severe COPD. METHODS: This Phase IIb, multicenter, randomized, double-blind, 7-day, crossover study compared GP MDI 28.8, 14.4, and 7.2 μg with placebo MDI (all administered as two inhalations, twice daily). The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV(1)) on Day 8. Secondary endpoints included FEV(1) area under the curve from 0 to 2 hours (AUC(0–2)) and peak change from baseline in FEV(1) on Days 1 and 8 and forced vital capacity AUC(0–2) on Day 8. Safety was also assessed. ClinicalTrials.gov Identifier: NCT03256552; http://www.ClinicalTrials.gov. RESULTS: Sixty-six patients were randomized and 62 were included in the modified intent-to-treat population (mean age 67.5 years). All three GP MDI doses significantly improved change from baseline in morning pre-dose trough FEV(1) on Day 8 compared with placebo MDI (least squares mean differences 108–131 mL; all p<0.0001). Significant improvements in secondary efficacy endpoints were also observed for all three GP MDI doses compared with placebo MDI (all p<0.0001). Dose–response plateaued at GP MDI 14.4 μg. No significant safety findings were observed with any GP MDI dose or placebo MDI. CONCLUSIONS: The results of this study suggest that GP MDI 14.4 μg (7.2 μg per inhalation) is the most appropriate dose for use in Phase III studies in Japanese patients with moderate-to-severe COPD. Dove Medical Press 2018-04-13 /pmc/articles/PMC5905841/ /pubmed/29695902 http://dx.doi.org/10.2147/COPD.S159246 Text en © 2018 Fukushima et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fukushima, Yasushi
Nakatani, Yuji
Ide, Yumiko
Sekino, Hisakuni
St Rose, Earl
Siddiqui, Shahid
Maes, Andrea
Reisner, Colin
Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
title Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
title_full Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
title_fullStr Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
title_full_unstemmed Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
title_short Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
title_sort randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium mdi in japanese patients with moderate-to-severe copd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905841/
https://www.ncbi.nlm.nih.gov/pubmed/29695902
http://dx.doi.org/10.2147/COPD.S159246
work_keys_str_mv AT fukushimayasushi randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT nakataniyuji randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT ideyumiko randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT sekinohisakuni randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT stroseearl randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT siddiquishahid randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT maesandrea randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd
AT reisnercolin randomizeddoubleblindplacebocontrolledtrialtoassesstheefficacyandsafetyofthreedosesofcosuspensiondeliverytechnologyglycopyrroniummdiinjapanesepatientswithmoderatetoseverecopd